86 results about "Nerve growth factor" patented technology

The invention provides a nerve growth factor functionalized exosome as well as a preparation method and application thereof. The functionalized exosome can activate a Wnt / beta-catenin signal channel to maintain dryness of corneal limbal stem cells (LSCs) so as to promote corneal epithelium repair, can activate a cAMP signal channel to relieve inflammatory response and promote corneal nerve regeneration, and can be used for treating or relieving corneal chemical burns, including relieving inflammatory response, reducing stromal scar formation and inhibiting corneal neovascularization. Corneal epithelium repair and nerve regeneration are promoted.

The invention discloses a neural microelectrode for electrical stimulation combined with drug release and a preparation method thereof.The neural microelectrode comprises a first flexible substrate layer, a drug-loaded slow-release layer, a second flexible substrate layer, a conductive layer and an insulating covering layer, and the drug-loaded slow-release layer contains chitosan microspheres embedded with drugs; the medicament comprises nerve growth factors and / or anti-inflammatory drugs, a plurality of drug release holes are distributed in the insulating covering layer, an electrode contact is arranged at one end of the conducting layer, a lead connector is electrically arranged at the other end of the conducting layer, and openings for exposing the electrode contact and the lead connector are correspondingly formed in the two ends of the insulating covering layer respectively. According to the neural microelectrode provided by the invention, the drug-loaded slow-release layer is integrated in the neural microelectrode, so that a space for storing a drug does not need to be additionally processed on the membrane layer, and the drug does not need to be additionally loaded, so that the production and processing are relatively convenient and rapid; after the neural microelectrode is implanted into a corresponding tissue in a body, the drug-loaded sustained-release layer can be gradually degraded to slowly release a medicament for repairing nervous tissues or avoiding rejection reaction in a long-acting manner.

The invention discloses a culture medium for adipose-derived stem cells, and particularly relates to the technical field of stem cell culture. The culture medium comprises a basic culture medium and nerve-vascular niche components, wherein the basic culture medium comprises DMEM / F12, 10% of human-derived platelet lysate and 1% of antibiotic solution; the nerve-vascular niche comprises the following components: a Slit3 recombinant protein, a nerve growth factor-beta, a glial cell-derived neurotrophic factor, a lysyl oxidase inhibitor, dexamethasone, 3-isobutyl-1-methylxanthine and insulin. The traditional fetal calf serum is replaced by the human-derived platelet lysate, so that the risks of immunological rejection and pathogen pollution are avoided; through the synergistic effect of nerve-vessel niche factors, blood vessel maturation and innervation are promoted, programmed mechanical stretching culture is combined, the adipogenic differentiation efficiency of adipose-derived stem cells is remarkably improved, and engineered adipose tissue which is huge in lipid droplet, compact in structure and provided with a nerve-vessel network is formed.

The present disclosure relates to a biomarker for distinguishing between depression and bipolar disorder and uses thereof, elucidating a composition for distinguishing between depression and bipolar disorders and a method for providing information for distinguishing between depression and bipolar disorder, using same, wherein the composition is based on a biomarker composition comprising eotaxin, nerve growth factors (NGF), tumor necrosis factor-α (TNF-α), glial cell derived neurotrophic factor (GDNF), interleukin-1β (IL-1β), and serum soluble CD40 Ligand (sCD40L) within a serum sample and includes an agent for measuring the expression level of each of the six biomarker proteins.

The present application relates to a nutritional composition, a product comprising the same and use thereof in the preparation of a product for alleviating synaptic plasticity impairment of a body. The nutritional composition comprises: docosahexaenoic acid (DHA) and / or a metabolic precursor thereof, sodium hyaluronate (SH), and lactoferrin (LF). When docosahexaenoic acid (DHA), sodium hyaluronate (SH) and lactoferrin (LF) are used in combination, they can synergistically alleviate synaptic plasticity impairment of a body, in particular, increase nerve growth factor (NGF) content and / or brain-derived neurotrophic factor (BDNF) content in PC12 cells of the body, and / or increase expression of synaptic-related proteins in PC12 cells of the body.

The present application relates to a kind of water gel support prepared by self-assembled polypeptide and the use of support obtained therefrom, the preparation method includes: 1) self-assembled peptide sequence is linked nerve growth factor analog peptide by covalent bond to obtain bonded functional polypeptide;2) macrophage is separated and cultured, and is induced to be " alternative activation " anti-inflammatory M2 macrophage, obtain culture supernatant and carry out filtration, obtain filtered cell culture supernatant;3) filtered cell culture supernatant is mixed with bonded functional polypeptide, obtain mixed solution and adjust the concentration of the mixed solution, the bonded functional polypeptide self-assembles and forms water gel support.The present application uses M2 macrophage condition culture supernatant to construct regenerative microenvironment, combines polypeptide functional water gel support, realizes better overall interaction, and prepares the water gel support that can supplement and regulate nerve regeneration, the support can promote nerve cell regeneration behavior, provides new selection for tissue engineering biomaterials.

The invention relates to application of graphene-(RADA-IKVAV)-pranoprofen, eye drops and a preparation method of the eye drops. The invention relates to graphene-(RADA-IKVAV)-pranoprofen, the graphene-(RADA-IKVAV)-pranoprofen comprises graphene-polyacrylic acid, self-assembled oligopeptide RADA-IKVAV and pranoprofen, the self-assembled oligopeptide RADA-IKVAV is connected with the graphene-polyacrylic acid through a chemical bond, and the pranoprofen is loaded on the surface of the graphene-polyacrylic acid. The eye drops provided by the invention comprise graphene-(RADA-IKVAV)-pranoprofen, so that the drug loading capacity of pranoprofen in the eye drops is increased, the bioavailability of drugs is improved, and the eye drops are used for inhibiting eye inflammation; the coupled oligopeptide RADA-IKVAV simulates an extracellular environment, provides a suitable microenvironment for eyes, promotes nerve repair and regeneration by influencing nerve growth factors, and promotes optic nerve repair.

The invention provides a cleaning and preserving fluid for fetal brain tissues and a preserving method thereof, and belongs to the technical field of tissue preservation. The cleaning and preserving fluid comprises trehalose, nerve growth factors, a GlutaMAX supplement, Y27632, S-nitrosoglutathione, tert-butylhydroquinone, a Versene solution and polyvinylpyrrolidone, compared with a traditional tissue preserving fluid, the cleaning and preserving fluid not only can improve the purity of neural stem cells, but also can maintain the activity and the yield of the neural stem cells in fetal brain tissue, and the cleaning and preserving fluid has the advantages that the cleaning and preserving fluid is simple in structure and convenient to use. The structural integrity of the cells is guaranteed, a high-quality sample is provided for subsequent research on proliferation, differentiation and the like of the neural stem cells, and the method has a wide application prospect.

The present disclosure provides recombinantly manufactured fusion proteins comprising a nerve growth factor (NGF) protein fragment or an analog thereof linked to a canine Fc fragment. Embodiments include the administration of the fusion proteins to patients to reduce pain symptoms in dogs suffering from a pain-associated ailment such as osteoarthritis. Exemplary Fc fusion proteins and pharmaceutical formulations of exemplary Fc fusion proteins are provided, in addition to methods of use and preparation.

The present invention relates to Nerve growth factor (NGF) or a mutein thereof, for use in the treatment of Niemann-Pick type C in a subject.

The invention discloses a whitening and anti-aging mask formula based on dogwood. The whitening and anti-aging mask formula based on dogwood is prepared from the following raw materials in parts by mass: 5 to 15 parts of dogwood extract, 2 to 8 parts of vitamin C powder, 1 to 3 parts of polyphenol compound, 1 to 5 parts of glycerinum, 2 to 4 parts of hyaluronic acid, 3 to 9 parts of plant essence, 2 to 6 parts of vegetable oil, 4 to 12 parts of seaweed extract and 1 to 3 parts of polyether-201. 1-3 parts of nerve growth factors, 2-6 parts of DNA (deoxyribonucleic acid) repair enzyme, 0.1-0.3 part of snake venom essence, 1-3 parts of plant stem cells and 20-30 parts of deionized water, components in the snake venom essence can stimulate synthesis of collagen and increase skin elasticity, so that wrinkles and fine wrinkles are reduced, the skin looks younger and tighter, certain antioxidant capacity is achieved, and the skin care effect is good. Free radicals can be neutralized, the damage of environmental pollution and ultraviolet radiation to the skin is reduced, and the aging process of the skin is delayed.

The invention provides multifunctional hydrogel carrying neural stem cells. The multifunctional hydrogel mainly comprises the following components: chitosan, beta-sodium glycerophosphate, edaravone, nerve growth factors and the neural stem cells, the invention also provides a method for preparing the multifunctional hydrogel, which comprises the following steps: preparing temperature-sensitive hydrogel by taking a chitosan solution and a beta-sodium glycerophosphate solution as matrixes, preparing an edaravone-nerve growth factor mixed solution, and preparing the edaravone-nerve growth factor composite hydrogel. Sequentially adding a neural stem cell suspension and the mixed solution into a hydrogel system to obtain the multifunctional hydrogel carrying the neural stem cells. The multifunctional hydrogel disclosed by the invention realizes high-efficiency integration of three core functions of temperature-sensitive positioning, drug sustained-release microenvironment regulation and control and cell proliferation and differentiation support, and can remarkably promote spinal cord injury repair.

The invention discloses a spinal cord injury repair multifunctional composite material and a preparation method and application thereof. The material is prepared from chitosan-loaded nano manganese dioxide, resveratrol and nerve growth factors. The method comprises the following steps: adding a dispersing agent and modified nano-manganese dioxide into a chitosan solution, and then adding a resveratrol solution and a diluted nerve growth factor solution into the chitosan solution to obtain a mixed solution; finally, the mixed solution is subjected to freeze drying treatment, and the spinal cord injury repairing multifunctional composite material is obtained. The spinal cord injury repair multifunctional composite material can be used as a medical stent material for treating spinal cord injury. Through the innovation of drug controlled release (pH response + slow release) and multi-mechanism cooperation (oxidation resistance / inflammation resistance / regeneration), the limitation of a single mode of spinal cord injury treatment is broken through, and a comprehensive strategy with a wide application prospect is provided for SCI repair.

The present invention relates to a method for attenuating retinal cell damage and other neuronal cell damage outside the central nervous system associated with reduced supply of neurotrophin, i.e., nerve growth factor (NGF), induced by glaucoma and other forms of neurodegeneration by orally administering a therapeutically effective amount of an aqueous extract of spearmint to a subject.

Disclosed herein are compounds and pharmaceutical compositions useful for treating, preventing, reducing, or ameliorating diseases or conditions associated with neurodegenerative disorders. Without being bound by theory, the disclosed compounds and compositions are believed to selectively target tropomyosin receptor kinase A (TrkA) receptor-mediated pro-survival signaling pathways or the nerve growth factor (NGF) or the neurosteroid dehydroepiandrosterone (DHEA) and may prevent, treat, reduce, or ameliorate neurodegeneration.

This invention belongs to the pharmaceutical field and relates to a human nerve growth factor composition. This invention provides a human nerve growth factor composition that can be administered via multiple routes, maintains good stability without cryopreservation, and does not require fixed accessories, simplifying operation and improving the convenience of medication.

The application belongs to the technical field of molecular diagnosis, and particularly relates to a group of extracellular vesicle proteins as biomarkers for diagnosing abdominal aortic aneurysm and application. The application early diagnoses abdominal aortic aneurysm through determination of circulating extracellular vesicle protein markers, and provides an effective tool for diagnosis of abdominal aortic aneurysm. The extracellular vesicle protein marker is any one or two or more molecular marker combinations of interleukin-4 (IL-4), interleukin-6 (IL-6), monocyte chemotactic protein-1 (MCP-1), nerve growth factor (Neurturin) and tumor suppressor M (Oncostatin-M). The application uses proteins in extracellular vesicles as specific markers for early diagnosis of abdominal aortic aneurysm, which is a less applied field in current early diagnosis of AAA. The specific proteins in EVs may be directly related to the pathological process of AAA, and are different from conventional serum markers, and have higher specificity and sensitivity.

This invention discloses an injectable hydrogel for long-term sustained release of NGF and CNTF, its preparation method, and its application in visual system diseases. The bioactive factor sustained-release hydrogel of this invention comprises a hydrogel matrix and bioactive factor microspheres loaded on the matrix; the raw materials for preparing the hydrogel matrix include chitosan, type II collagen, and hyaluronic acid; the bioactive factor microspheres comprise an inner core and a capsule wall, the inner core being a bioactive factor selected from one or both of ciliary neurotrophic factor and nerve growth factor, and the capsule wall being a polylactic acid-glycolic acid copolymer. This hydrogel can achieve long-term stable release of NTF, activating endogenous neural stem cells in the retina to generate new retinal ganglion cells. It exhibits high safety, good injectability, and a long sustained-release period, and can be used to prepare drugs for treating visual system diseases such as glaucoma, optic nerve damage, and macular degeneration.

The invention provides a functionalized cornea stroma lens acellular scaffold as well as a preparation method and application thereof, and belongs to the technical field of biomedical materials. A functional cornea-derived natural extracellular matrix (ECM) scaffold is used as a core, a decellularized freeze-drying technology is combined to prepare a decellularized freeze-dried lens (LDL) convenient to store, and an oxidized heparin interface modification technology is used to enrich active factors through an electron capture principle so as to construct a functional ECM platform. And the safety and effectiveness are evaluated in vivo and in vitro. Research results show that the system has long-term storage capacity and low immunogenicity, can prolong the action duration of a nerve growth factor (NGF), effectively inhibits postoperative inflammation and fibrosis in a rabbit cornea stroma lens transplantation model, supports stroma cell colonization and nerve reinnervation, and remarkably promotes cornea tissue repair and regeneration. The novel functional ECM platform developed by the invention provides a new thought and reference for the ECM stent in the field of cornea regeneration treatment.

The invention discloses a resveratrol and nerve growth factor loaded chitosan-polydopamine modified 3D printing biological material as well as a preparation method and application thereof in spinal cord injury repair, the structure and function of the biological material simulate a natural extracellular matrix (ECM) tissue structure to fill cavities in a spinal cord injury area, and tissue regeneration can be guided; meanwhile, the compound can be used as a carrier of medicines, cells or bioactive factors. According to the material, a three-dimensional porous PLA support with an accurate structure is printed through a fused deposition modeling (FDM) technology to serve as a carrier for cell compatibility and physical supporting, CS is loaded in the three-dimensional porous PLA support through a freeze drying technology, PDA carrying NGF is loaded on the surface of the three-dimensional porous PLA support, Res is loaded through the physical adsorption effect, and the multifunctional 3D biological composite material for spinal cord injury repair is prepared. Through the synergistic effect of anti-inflammatory, anti-oxidation, anti-apoptosis and other ways, a microenvironment beneficial to nerve regeneration is created together, and functional recovery after spinal cord injury is significantly promoted.

Provided herein are compositions and methods for the inhibition of nerve growth factor (NGF) and the treatment / prevention of atrial fibrillation. In particular, inhibitors of NGF expression are administered to the myocardial tissue of a subject to treat or prevent atrial fibrillation and / or autonomic nerve sprouting in the atria.

The invention discloses application of an ophthalmic preparation containing a recombinant human beta-nerve growth factor. The ophthalmic preparation can be used for treating dry eyes. The ophthalmic preparation containing the recombinant human beta-nerve growth factor comprises 5 to 1000 [mu] g / ml of the recombinant human beta-nerve growth factor, 20 to 70 mg / ml of trehalose, 5 to 30 mg / ml of mannitol and 1 to 13 mg / ml of polyvinyl alcohol.

The invention relates to an anti-recombinant cat nerve growth factor egg yolk antibody as well as a preparation method and application thereof. The preparation method comprises the following steps: preparing an antigen recombinant cat nerve growth factor by utilizing genetic engineering prokaryotic expression; immunizing laying hens by using the antigen recombinant cat nerve growth factors, and collecting eggs; the method comprises the following steps: cleaning eggs, separating yolk, mixing with normal saline to obtain a first mixed solution, adding chloroform into the first mixed solution, carrying out water bath to obtain a second mixed solution, centrifuging to obtain a yolk antibody extracting solution, and further purifying the yolk antibody extracting solution to obtain the yolk antibody, the amino acid of the recombinant cat nerve growth factor is the 113th-238th amino acid of the cat nerve growth factor, the gene sequence for coding the recombinant cat nerve growth factor is shown as SEQ ID NO: 8, and the prepared egg yolk antibody has excellent antigenicity, is more convenient to obtain, can effectively reduce the cost, is more beneficial to production, and has wide application prospects.

The present invention relates to compositions comprising modified virus-like particles (VLPs) of Cucumber Mosaic Virus (CMV), and in particular to modified VLPs of CMV comprising chimeric CMV polypeptides which comprises a stretch of consecutive negative amino acids selected from aspartic acid or glutamic acid to which nerve growth factor (NGF) antigens are linked as well as pharmaceutical compositions thereof, which compositions preferably serve as vaccine platform for generating immune responses, in particular antibody responses, against said NGF antigens linked to the modified CMV VLPs.

The invention relates to a biomarker for distinguishing depression and bipolar affective disorder and application thereof, in particular to a composition for distinguishing depression and bipolar affective disorder, a method for providing information for distinguishing depression and bipolar affective disorder through the composition and the like, and the composition comprises a preparation. The preparation detects the expression level of each of six proteins of a biomarker based on a biomarker composition for distinguishing depression from bipolar affective disorder, and the biomarker composition comprises an eosinophilic granulocyte chemokine (Eotaxin), a nerve growth factor (NGF, NGF, NGF, NGF, NGF, NGF, NGF, NGF, NGF, NGF, NGF, NGF, NGF, NGF, NGF, NGF, NGF, NGF, NGF, NGF, NGF, NGF, NGF, NGF and NGF in a serum sample. The invention relates to a tumor necrosis factor-alpha (tumor necrosis factor-alpha, TNF-alpha), a glial cell derived neurotrophic factor (GDNF), an interleukin-1beta (interleukin-1beta, IL-1beta), and a serum soluble CD40 ligand (sCD40L), in particular to a tumor necrosis factor-alpha (tumor necrosis factor-alpha, TNF-alpha), a glial cell derived neurotrophic factor (GDNF), an interleukin-1beta (interleukin-1beta, IL-1beta), a tumor necrosis factor-alpha (tumor necrosis factor-alpha, TNF-alpha) and a serum soluble CD40 ligand (sCD40L).

Some embodiments of the present disclosure relate to one or more compositions that upregulate the production of one or more sequences of mRNA. The sequences of mRNA may encode for translation of a target biomolecule, thereby causing an increase in bioavailability of the target biomolecule within a subject that is administered the one or more compositions. In some embodiments of the present disclosure, the target biomolecule is a fusion protein with an Fc fragment, such as a toll-like receptor 3-Fc (TLR3-Fc). In some embodiments of the present disclosure, the target biomolecule is toll-like receptor 9-Fc (TLR9-Fc). In some embodiments of the present disclosure, the target biomolecule is deoxyribonuclease I-Fc (DNAse I-Fc). In some embodiments of the present disclosure, the target biomolecule is neural growth factor-Fc (NGF-Fc). In some embodiments of the present disclosure, the target biomolecule is insulin-Fc.

The present invention relates to a cosmetic composition comprising a combination of nerve growth factor (NGF) inhibitors, that is particularly of use in the topical treatment of pruritus, in particular, that observed in the case of psoriasis or of atopic dermatitis, of chronic urticaria and also of senile pruritus. The invention is directed towards a composition comprising an ambora extract and a green tea extract.

The present disclosure provides recombinantly manufactured fusion proteins comprising a nerve growth factor (NGF) protein fragment or an analog thereof linked to a canine Fc fragment. Embodiments include the administration of the fusion proteins to patients to reduce pain symptoms in dogs suffering from a pain-associated ailment such as osteoarthritis. Exemplary Fc fusion proteins and pharmaceutical formulations of exemplary Fc fusion proteins are provided, in addition to methods of use and preparation.

The invention discloses a biomarker for diagnosing pulmonary fibrosis and application of the biomarker, and belongs to the technical field of biomarkers in clinical medicine. The biological marker for preparing and diagnosing pulmonary fibrosis is a nerve growth factor NGF, the nerve growth factor NGF can remarkably promote differentiation of lung fibroblast MRC5 cells, and along with expression increase of a receptor TrkA of the lung fibroblast MRC5 cells, the migration capacity and the multiplication capacity of the lung fibroblast MRC5 cells are remarkably enhanced. Meanwhile, the NGF also aggravates the formation of the BLM-induced pulmonary fibrosis of the mouse. Therefore, the nerve growth factor NGF as the biomarker has accurate and specific detection and auxiliary diagnosis on pulmonary fibrosis, especially idiopathic pulmonary fibrosis (IPF).